Nexag (Tranexamic Acid)

Tranexamic Acid, the active ingredient in Nexag, is an antifibrinolytic presented as an oral tablet for systemic use. It works by reducing excessive bleeding and is indicated for heavy menstrual bleeding, trauma‑related hemorrhage, and surgical bleeding in adult patients.

GNH USA supplies Nexag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed to healthcare providers across multiple regions. Our supply chain ensures product integrity and timely delivery to meet clinical demand.

Tranexamic Acid is used to reduce bleeding by stabilizing blood clots in several clinical settings.

Menorrhagia: decreases menstrual blood loss and improves quality of life. Trauma‑related bleeding: helps control hemorrhage following injury. Surgical bleeding: minimizes intra‑operative and post‑operative blood loss.

Tranexamic Acid is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Abdominal pain - Headache - Dizziness

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Visual disturbances (blurred vision, retinal artery occlusion) - Severe allergic reactions (rash, angioedema, anaphylaxis) - Hypotension - Seizures (rare)

Before prescribing Tranexamic Acid, clinicians should consider several safety aspects. - Assess thrombotic risk: evaluate history of clotting disorders. - Monitor renal function: adjust use in patients with impaired kidney function. - Use with caution in active intravascular clot: avoid if recent thrombus is present. - Review concomitant anticoagulant or antiplatelet therapy: adjust dosing as needed. - Avoid in patients with known hypersensitivity to tranexamic acid. - Store at ambient temperature: keep in the original pack, protect from moisture.

Tranexamic Acid may interact with other medicines that affect coagulation or fibrinolysis.

Major Interactions (Avoid): - Thrombolytic agents (e.g., alteplase, streptokinase): antagonizes their clot‑dissolving effect. - Procoagulant agents (e.g., activated factor VII): may increase risk of thrombosis.

Moderate Interactions (Monitor Closely): - Oral contraceptives and hormone replacement therapy: may elevate clot risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can increase gastrointestinal irritation. - Anticoagulants (e.g., warfarin, DOACs): may require dose adjustment. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor bleeding parameters.